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nderstanding
Diastolic Heart Failure”
he Tip of the Iceberg*
ick A. Nishimura, MD, FACC,
issam Jaber, MD
ochester, Minnesota
eart failure (HF) is a growing epidemic and is now the
ost common primary diagnosis of all hospitalized patients
n the U.S. Thus, the prevention, diagnosis, and treatment
f patients with HF have substantial implications for health
are from both the clinical and resource standpoint. When
patient presents with signs and symptoms of HF, clini-
ians expect to see a dilated poorly contractile left ventricle
LV). Yet almost one-half of all patients presenting with
F have a normal ejection fraction (EF) (1) and comprise a
nique subset known as “heart failure with normal ejection
raction” (HFnlEF). The prevalence of HFnlEF has been
radually rising over the past 2 decades. Although therapies
ave proven effective in reducing mortality from HF with
educed EF, mortality from HFnlEF remains unchanged
2). No therapies thus far have been proven to correct the
bnormalities seen in HFnlEF, halt its progression, or
educe its mortality. With such a huge potential impact on
ardiovascular medicine, there is an urgent necessity to
etermine the pathophysiology of this disorder and use this
nowledge to develop appropriate therapeutic strategies.
See page 687
The clinical presentation of symptoms and signs of HF
ith documentation of a preserved EF has been the main
ntry criterion for the few therapeutic trials of HFnlEF,
uch as the CHARM (Candesartan in Heart Failure: Assess-
ent of Reduction in Morbidity and mortality)-Preserved trial
3). It has been controversial as to whether noninvasive
bjective evidence of impaired diastolic filling is required for
iagnosis of HFnlEF (4,5). In this issue of the Journal,
ersson et al. (6) present their Doppler echocardiographic
ata in a substudy that included a small group of the more
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.s
From the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic
ollege of Medicine, Rochester, Minnesota.han 3,000 patients of the CHARM-Preserved trial. These
atients underwent an echocardiogram a median of 17.7
onths after randomization and were classified into 4
roups on the basis of the severity of diastolic abnormalities
een on the transmitral flow velocity pattern: normal,
elaxation abnormality, pseudonormal, and restrictive dis-
ase. Not all centers were using mitral annular tissue
oppler imaging (7), so N-terminal pro-B-type natriuretic
eptide (NT-proBNP) was used in 61% of all patients to
istinguish normal from pseudonormal patterns. The study
howed that the primary end point of cardiovascular death
r HF hospitalization after a mean follow-up of 18 months
as strongly related to the severity of diastolic abnormality.
nterestingly, the study found that 12% of all patients
ndergoing echocardiography had an EF of 35%. Of the
emaining patients included in the study, 33% had a normal
iastolic filling pattern.
This study does have limitations. The accuracy of the
ssessment of diastolic function might be questioned, as
issue Doppler was not routinely used. The authors included
atients with concomitant abnormalities such as atrial fi-
rillation, and the noninvasive assessment of patients with
hese rhythms has not been well studied. The echo Doppler
ssessment of diastolic filling was done 18 months after
andomization and it would have been of greater clinical
alue to report on the Doppler parameters at entry into the
tudy. Finally, the classification of diastolic function using
T-proBNP is debatable (8); in a community-based study
y Redfield et al. (9), the optimal sensitivity and specificity
f BNP to detect moderate-to-severe diastolic dysfunction
as only 75% and 69%, respectively. This means that in a
opulation where the prevalence of diastolic dysfunction is
7% (as found in the current study by Persson et al. [6]), 28%
f the patients would be misclassified if BNP levels were used
or the diagnosis of moderate diastolic dysfunction (9).
Despite the limitations, the study is important for 2
easons. First, it confirms our suspicions that in patients
ith a clinical diagnosis of HFnlEF, the more severe the
rade of diastolic dysfunction, the worse the clinical out-
ome. This means that assessment of the degree of diastolic
lling abnormality on Doppler echocardiography provides
mportant information for risk stratification. Second, the
tudy found that objective evidence of diastolic dysfunction
as present in only 67% of the patient population. This
ould imply that the clinical criteria used in large random-
zed trials such as the CHARM-Preserved trial may be
nadequate for entry criteria into studies examining the
ffect of drugs on outcome in patients with HFnlEF. If the
riteria for “normal diastolic function” contained in this
tudy are correct, there could be a significant inherent bias
n the CHARM-Preserved study as well as other pending
herapeutic studies for patients with HFnlEF.
The findings from this study indicate that the current
oninvasive assessment of diastolic filling is useful for risk
tratification and necessary for entry diagnosis into any
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Editorial Comment February 13, 2007:695–7herapeutic trial of patients with HFnlEF. However, al-
hough progress has been made, current approaches are
verly simplistic, and we are just seeing the “tip of the
ceberg.” A major problem with HFnlEF is that there is a
ack of basic understanding and consensus on the patho-
hysiology, diagnostic strategies, and classification of this
mportant disease (10–12). As opposed to HF with de-
ressed EF, in which the pathophysiology and subsequent
reatment have been extensively studied, there is still con-
iderable controversy regarding the perturbations in cardio-
ascular function responsible for HFnlEF.
Figure 1 Pressure Tracings From 2 Different Patients With HFn
Patient A has hypertensive heart disease and patient B has nonobstructive hypert
right are after intravenous nitroprusside (patient A) and intracoronary enalaprilat (p
pressures decreased in patient A because of a decrease in LV systolic pressure.
sures dropped without a significant change in the LV systolic pressure. These exa
responsible for increased diastolic filling pressures in patients with heart failure wAlthough there is agreement that the clinical presentation
f HFn1EF is simply the patient with signs and symptoms
f HF and a preserved EF, there is no well-accepted
xplanation as to why this occurs. Three different patho-
hysiologic theories have been advanced. The first postulate
s that HFnlEF is due to an increase in the intrinsic muscle
tiffness (13). The second pathophysiologic concept is that
FnlEF is due to increased systolic ventricular and vascular
tiffening that results in enhanced sensitivity to volume
verload (14). Maurer et al. (15) recently reported a group of
ypertensive HFnlEF patients with normal systolic ventric-
cardiomyopathy. The tracings on the left are recorded at baseline; those on the
B). The pulmonary capillary wedge and the left ventricular (LV) end-diastolic
in contrast to patient B, in whom the left atrial (LA) and LV end-diastolic pres-
implicate the presence of different underlying pathophysiologic mechanisms
mal ejection fraction (HFnlEF). PCWP  pulmonary capillary wedge pressure.lEF
rophic
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February 13, 2007:695–7 Editorial Commentlar and vascular stiffness but larger LV sizes. Their findings
upport a third theory: HFnlEF is due to LV remodeling
nd dilatation with volume-dependent elevation of filling
ressures. These different mechanisms may have important
mplications for differing therapeutic strategies.
The wide diversity in the pathophysiologic explanations
or HFnlEF stems from the difficulty in studying and
easuring the complex interplay of multiple interrelated
vents that contribute to diastolic filling of the LV. The
ommonly used Doppler-derived indexes are useful in
etermination of filling pressures, but they are only indirect
easures of ventricular filling (16,17), and they do not
rovide information on the intrinsic diastolic properties of
he LV (12). The intrinsic diastolic properties of the LV are
est studied by simultaneous left ventricular volume, pres-
ure, and stress/strain relationships under different loading
onditions. This is currently possible only through complex
nvasive hemodynamic studies, which have limited applica-
ility in large patient populations and are not widely
vailable to most investigators (18). However, continued
fforts from these invasive studies, combined with the
evelopment and assessment of newer, more sophisticated
oninvasive imaging modalities using 3-dimensional echo-
ardiography, tissue Doppler strain imaging, speckle track-
ng, and high-resolution magnetic resonance imaging scan-
ing, will be necessary to fully understand this disorder.
The true pathophysiologic mechanism of “diastolic dys-
unction” needs to be elucidated, for without this knowledge
he diagnostic and therapeutic strategies for patients with
FnlEF cannot be advanced. We need to determine whether
FnlEF is one disease or if there are multiple distinct
athophysiologic disturbances leading to one clinical picture.
hese unknowns are illustrated in Figure 1, which shows
he highly variable responses of diastolic function to inter-
entions in individual patients. Our eventual understanding
ill have significant implications in directing therapy:
hould we only lower afterload and preload, or should we be
xamining drugs with the potential to affect myocardial
elaxation, stiffness, and remodeling? We suspect that we
ill find a wide spectrum of pathophysiologic processes
ausing HFnlEF, which will require a wide spectrum of
reatment options targeted to the underlying pathophysiol-
gy. This group of patients with HF and preserved EF is
ncreasing in its prevalence without a foreseeable reduction
n mortality. As HFnlEF is becoming the most common
orm of HF, there is a great need for coordinated efforts to
ully address this problem.
1eprint requests and correspondence: Dr. Rick A. Nishimura,
ayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905.
-mail: rnishimura@mayo.edu.
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